Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
- 18 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (10), 2947-2958
- https://doi.org/10.1158/1078-0432.ccr-20-3418
Abstract
Purpose: To investigate the different roles of heterogeneous natural killer (NK) cell subpopulations in multiple myeloma (MM) and to identify NK cell subsets that support the robust anti-myeloma activity of daratumumab via antibody-dependent cellular cytotoxicity (ADCC). Experimental design: We performed single-cell RNA sequencing of NK cells from newly diagnosed MM (NDMM) patients and delineated adaptive NK cells in their bone marrow (BM). We further characterized the distinct immunophenotypic features and functions of adaptive NK cells by multicolor flow cytometry in 157 NDMM patients. Results: Adaptive NK cells exhibit a significantly lower level of CD38 expression compared with conventional NK cells, suggesting that they may evade daratumumab-induced fratricide. Moreover, adaptive NK cells exert robust daratumumab-mediated effector functions ex vivo, including cytokine production and degranulation, compared with conventional NK cells. The composition of adaptive NK cells in BM determines the daratumumab-mediated ex vivo functional activity of BM NK cells in NDMM patients. Unlike conventional NK cells, sorted adaptive NK cells from the BM of NDMM patients exert substantial cytotoxic activity against myeloma cells in the presence of daratumumab. Conclusions: Our findings indicate that adaptive NK cells are an important mediator of ADCC in MM and support direct future efforts to better predict and improve the treatment outcome of daratumumab by selectively employing adaptive NK cells.Keywords
Other Versions
Funding Information
- Ministry of Science and ICT, Republic of Korea (NRF-2020R1C1C1010618)
This publication has 65 references indexed in Scilit:
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibClinical Cancer Research, 2015
- Antibody-Mediated Response of NKG2Cbright NK Cells against Human CytomegalovirusThe Journal of Immunology, 2015
- Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected IndividualsImmunity, 2015
- Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector FunctionImmunity, 2015
- Signatures of Human NK Cell Development and Terminal DifferentiationFrontiers in Immunology, 2013
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effectBlood, 2011
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaMolecular Cancer Therapeutics, 2009
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor CellsClinical Cancer Research, 2008
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple MyelomaClinical Cancer Research, 2008